JPRN-UMIN000031039已完成未知
Comparison of clinical efficacy between fluticasone propionate/ formoterol (FFC) and fluticasone furoate/ vilanterol (VFC) in patients with asthma - Comparison of clinical efficacy between FFC and VFC
Ikeda Clinic0 个研究点目标入组 24 人开始时间: 2018年1月29日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with evident ACO or COPD comorbidities 2. Patients with antibiotic-resistant infections, deep mycosis, or tuberculosis disease 3. Patients who have been afflicted with a respiratory infection (viral infection) within 8 weeks prior to enrollment 4. Patients with a smoking history of at least 10 pack years 5. Patients who have experienced side effects from the use of ICS, LABA or the combined medications 6. Patients who have used systemic steroids within 4 weeks prior to enrollment 7. Patients with significant heart, liver, kidney disease or other clinically significant comorbidities 8. Patients who are pregnant, breastfeeding, or plan to become pregnant during the study period 9. Other patients who are judged unsuitable for inclusion by the investigators in the study
研究者
相似试验
尚未招募
不适用
Comparison of fluticasone/vilanterol vs fluticasone/salmeterol in stable copd patientsCTRI/2022/02/039895SRM college of pharmacy
已完成
不适用
Comparative efficacy of fluticasone furoate/umeclidinium/vilanterol(FF/UMEC/VI)versus budesonide/glycopyrrolate/formoterol fumarate(B/G/F) therapies in COPD patientsCOPDJPRN-UMIN000041089ippon Koukan Hospital50
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDEUCTR2017-004369-29-ESGlaxoSmithKline, S.A.3,000
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 21.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2017-004369-29-NLGlaxoSmithKline Research & Development Limited3,341
进行中（未招募）
1 期
Single Inhaler Triple Therapy (fluticasone furoate + vilanterol trifenatate + umeclidinium bromide) (inhaled) - COPDChronic Obstructive Pulmonary Disease (COPD) which may be called emphysema or chronic bronchitis.MedDRA version: 20.0 Level: LLT Classification code 10010952 Term: COPD System Organ Class: 100000004855EUCTR2017-004369-29-GBGlaxoSmithKline Research & Development Limited3,000